Management to hold a conference call at 10:00 a.m. EDT
JERUSALEM--(BUSINESS WIRE)--Jul. 30, 2014--
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that it
will release its unaudited financial results for the quarter ended June
30, 2014 on Wednesday, August 6, 2014, before the U.S. markets open.
The Company will host a conference call on Wednesday, August 6 at 10:00
a.m. EDT, featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive
Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating
Officer of BioLineRx. A presentation will be available on BioLineRx’s
website to accompany management’s remarks on the call. The conference
call will be available via webcast and can be accessed through the
Investor Relations section of BioLineRx’s website, www.biolinerx.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-407-2553 from the U.S. or
+972-3-918-0644 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will be available until August 9, 2014;
please dial 1-888-295-2634 from the U.S. or +972-3-925-5929
internationally.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid
leukemia (AML) and other hematological indications, which is in the
midst of a Phase 2 study; and BL-7010 for celiac disease, which is in
the midst of a Phase 1/2 study.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s ‘SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
Source: BioLineRx
Tiberend
Strategic Advisors, Inc.
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Andrew
Mielach, 212-375-2694
amielach@tiberend.com
or
BioLineRx
Tsipi
Haitovsky, +972-3-6240871
Public Relations
tsipihai5@gmail.com